Pro-inflammatory cytokine axis and angiogenesis markers

The pro-inflammatory cytokine axis and angiogenesis markers represent a complex network of signaling molecules that coordinate the body's inflammatory response and the formation of new blood vessels. Key components of the cytokine axis include Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-6 (IL-6), which drive systemic inflammation and activate downstream signaling pathways like JAK/STAT (Source: StatPearls, 'Cytokines'). Angiogenesis markers, such as Vascular Endothelial Growth Factor (VEGF), are often upregulated by these inflammatory signals, promoting the growth of new vasculature to support tissue repair or, pathologically, tumor growth (Source: NIH, 'Angiogenesis Inhibitors'). In diseases like cancer and rheumatoid arthritis, this axis is chronically overactive, leading to tissue destruction and disease progression (Source: PubMed, PMID: 30214644). Therapeutic strategies often involve monoclonal antibodies or small molecule inhibitors that target specific nodes within this network, such as Bevacizumab for VEGF or Infliximab for TNF-alpha, to decouple inflammation from pathological blood vessel growth (Source: PubChem). Because this term describes a broad physiological pathway rather than a single protein, it is primarily used in clinical research to categorize panels of biomarkers rather than as a specific drug target.

Other names

Inflammatory-angiogenic axisCytokine-angiogenesis signaling networkPro-inflammatory and pro-angiogenic panel

Inhibition of specific pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) or pro-angiogenic growth factors (e.g., VEGF) to suppress pathological inflammation and neovascularization.